PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.66%
Revenue growth under 50% of TSM's 21.29%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.42%
Gross profit growth under 50% of TSM's 24.08%. Michael Burry would be concerned about a severe competitive disadvantage.
12.38%
EBIT growth below 50% of TSM's 32.27%. Michael Burry would suspect deeper competitive or cost structure issues.
12.38%
Operating income growth under 50% of TSM's 32.27%. Michael Burry would be concerned about deeper cost or sales issues.
12.09%
Net income growth under 50% of TSM's 24.94%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.62%
EPS growth under 50% of TSM's 24.81%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
14.55%
Diluted EPS growth at 50-75% of TSM's 24.81%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
1.10%
Share count expansion well above TSM's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.07%
Diluted share count expanding well above TSM's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-52.37%
Negative OCF growth while TSM is at 22.65%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-58.37%
Negative FCF growth while TSM is at 23.91%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
176.31%
10Y revenue/share CAGR at 75-90% of TSM's 232.77%. Bill Ackman would press for new markets or product lines to narrow the gap.
29.17%
5Y revenue/share CAGR under 50% of TSM's 75.35%. Michael Burry would suspect a significant competitive gap or product weakness.
5.18%
3Y revenue/share CAGR under 50% of TSM's 73.46%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-0.16%
Negative 10Y OCF/share CAGR while TSM stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
321.47%
5Y OCF/share CAGR above 1.5x TSM's 107.85%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-6.42%
Negative 3Y OCF/share CAGR while TSM stands at 187.01%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
219.36%
Below 50% of TSM's 717.14%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
52.64%
5Y net income/share CAGR at 75-90% of TSM's 68.55%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
215.77%
3Y net income/share CAGR above 1.5x TSM's 72.21%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
394.74%
Equity/share CAGR of 394.74% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
94.82%
5Y equity/share CAGR above 1.5x TSM's 36.79%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
27.97%
3Y equity/share CAGR at 50-75% of TSM's 45.51%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.36%
AR growth well above TSM's 13.39%. Michael Burry fears inflated revenue or higher default risk in the near future.
-5.00%
Inventory is declining while TSM stands at 10.88%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.73%
Asset growth at 50-75% of TSM's 6.25%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
5.85%
Positive BV/share change while TSM is negative. John Neff sees a clear edge over a competitor losing equity.
-2.02%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.00%
R&D growth drastically higher vs. TSM's 9.88%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
5.52%
We expand SG&A while TSM cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.